Lessons learned from HIV-1 vaccine trials: new priorities and directions
- 18 April 2012
- journal article
- research article
- Published by Springer Nature in Nature Immunology
- Vol. 13 (5) , 423-427
- https://doi.org/10.1038/ni.2264
Abstract
A vaccine against human immunodeficiency virus (HIV) seems to be on the horizon. Correlates of risk of infection for the RV144 trial have been found. There is understanding of what makes HIV envelope–specific antibodies broadly neutralizing and new T cell vaccine approaches can overcome virus variability.Keywords
This publication has 64 references indexed in Scilit:
- Broad neutralization coverage of HIV by multiple highly potent antibodiesNature, 2011
- Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodiesCurrent Opinion in Immunology, 2011
- Profound early control of highly pathogenic SIV by an effector memory T-cell vaccineNature, 2011
- Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogensBiochemical and Biophysical Research Communications, 2009
- Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeysNature Medicine, 2009
- Adaptive immune features of natural killer cellsNature, 2009
- HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysisThe Lancet, 2008
- Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialPublished by Elsevier ,2008
- Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeysNature, 2008
- Rapid cloning of high-affinity human monoclonal antibodies against influenza virusNature, 2008